Forest Laboratories is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in people's lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Campral(R)** (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation, and Bystolic(R) (nebivolol), a beta-adrenergic receptor blocking agent indicated for the treatment of hypertension.
About Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the
U.S. subsidiary of Daiichi Sankyo Co., Ltd., one of Japan's leading
pharmaceutical companies and a global leader in pharmaceutical innovation
whose roots date back to 1899. The company is dedicated to the discovery,
development and commercialization of innovative medicines that improve the
lives of patients throughout the world. The primary focus of Daiichi
Sankyo's research and development is cardiovascular disease, including
therapies for dyslipidemia, hypertension, diabetes, and acute coronary
syndrome. The company is also pursuing the discovery of new medicines in
the areas of glucose metabolic disorders, infectious diseases, cancer, bone
and joint diseases, and immune disorders. For more information, visit
* AZOR is a trademark of Daiichi Sankyo, Inc.
**Campral is a registered trademark of Merck Sante s.a.s., a subsidiary of
Merck KGaA, Darmstadt, Germany.
|SOURCE Forest Laboratories, Inc.; Daiichi Sankyo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved